^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/31/2020
Excerpt:
Recommendation 3.2….For patients with BRAF-mutant (V600) unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): ipilimumab plus nivolumab followed by nivolumab…
DOI:
10.1200/JCO.20.00198
